Frequently asked questions
Find answers to commonly asked questions about Rejoyn, the prescription process, and
more.
Prescribing Rejoyn
Unlike wellness apps, the Rejoyn app is in a class of software-based treatments called prescription digital therapeutics (PDTs). Rejoyn is authorized by the FDA and requires a prescription from a healthcare provider.1
FDA device regulations define the pediatric population as any patient less than 22 years of age. Rejoyn is a medical device, and it is indicated for adults age 22+ with major depressive disorder who are on antidepressant medication.
There are 2 ways to prescribe Rejoyn: e-prescribe or refer for a virtual consult. If you are a licensed prescriber, you can prescribe Rejoyn through your electronic health record system. If you are a behavioral health clinician, you can refer patients for a virtual consult on the patient website.
Whether you e-prescribe or refer for a virtual consult, a patient's prescription will be sent directly to BlinkRx — this is the online pharmacy that dispenses access codes for Rejoyn.
Licensed prescribers can learn how to find BlinkRx in the electronic medical record here.
BlinkRx is an online pharmacy that specializes in digital products and dispenses Rejoyn. You can call 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays, and select from a list of menu options that will connect you to BlinkRx.
A patient's prescription will be sent directly to BlinkRx for processing, payment, and fulfillment.
- BlinkRx will follow up with your patient to collect payment. Please note that insurance providers may not cover prescription digital therapeutics. As a medical device, Rejoyn is reimbursable by HSA/FSA
- Once payment has been received, the pharmacy will text and email your patient within 24 to 48 hours with an access code for Rejoyn
- Your patient can download the Rejoyn app, set up their profile, and enter their access code to unlock treatment
FSA=flexible spending account; HSA=health savings account.
Access & Cost
The total cost of Rejoyn is $50* with a limited-time offer.
*Full price is $200. The limited time offer is available to those who do not pay for Rejoyn through insurance. Your patients may pay less if their insurance covers Rejoyn. The pharmacy will automatically check their coverage when processing the prescription.
Rejoyn end-to-end nurse support can answer questions about insurance coverage and reimbursement. Call 1-833-Y-REJOYN (1-833-973-5696), Monday through Friday, 8 AM to 8 PM ET, excluding holidays.
Patient Support
The following are topics you may want to cover with your patients. Rejoyn:
- Is the first and only add-on prescription treatment for depression symptoms that’s an app1
- Is authorized by the FDA1
- Provides 6 weeks of brain-training exercises and short skills-based therapy lessons1
- Reduced symptoms without side effects related to Rejoyn in a clinical trial (when added to an antidepressant)1
- Taps into the brain's natural ability to change (known as neuroplasticity)2,3
Visit the patient site for more patient-friendly resources.
Patients should plan to use Rejoyn 3 to 6 days a week for 6 weeks. Completing the CET brain-training exercises in Rejoyn takes about 20-30 minutes each, and the CBT-based video lessons take about 5 minutes each. Patients access treatment on their smartphone, on their own time. New exercises are unlocked at midnight the day they become available and expire at the end of each week. It’s important to note that at the end of each week, patients will lose access to the previous week’s exercises. They will, however, retain access to any lessons that have yet to be completed.
It’s ok to let your patients know that they may find the exercises challenging. Remind them that it’s not about the number of matches they make—as long as they are consistently completing the exercises, they’re doing them correctly. You can find more information to share with your patients here.
CBT=cognitive behavioral therapy; CET=cognitive-emotional training.
Nurse support, including adherence support, is available for your patients. Patients can opt in through the app at any time and agree to share data about their treatment with the nurse support program. Rejoyn end-to-end nurse support can provide patients with support calls to help them stay on track.
Results from the clinical trial suggest that patients who consistently completed the exercises and finished the program could benefit most from Rejoyn. In a clinical trial, 88.1% of patients (n=177) adhered to Rejoyn, completing at least 12 of the 18 treatment sessions.2
Let your patients know that Rejoyn Patient Support nurses are available to help check in on patient progress and help them stay on track at no charge.
If at any point you or your patients have questions about Rejoyn, call 1-833-Y-REJOYN (1-833-973-5696) to speak with a nurse Monday through Friday, 8 AM to 8 PM ET, excluding holidays.
More About Rejoyn
Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.2 Read more about Rejoyn here.
Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.2
Rejoyn does not monitor the patient’s symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.2
Recent research suggests neural network disruption can cause MDD symptoms. Imaging of patients with MDD shows hyperactivity in emotion centers like the amygdala and hypoactivity in cognitive areas like the prefrontal cortex. Rejoyn is different from medication and psychotherapy in that it was designed specifically to target dysregulated connectivity between these 2 regions, strengthening the connections between them. Read more here.1,2
Yes, you can experience CET firsthand at an upcoming congress:
- Pri-Med West | Anaheim, California | July 18 to 20, 2024
- APA | Seattle, Washington | August 8 to 10, 2024
- AAFP/FMX | Phoenix, Arizona | September 24 to 28, 2024
- Psych Congress | Boston, Massachusetts | October 29 to November 2, 2024
- NEI | Colorado Springs, Colorado | November 7 to 10, 2024
Rejoyn is authorized by the FDA for the treatment of adults age 22+ with MDD who are on antidepressant medication.1,2
Read about the safety and efficacy of Rejoyn here.
There were zero adverse events related to Rejoyn in a clinical trial of Rejoyn added to an antidepressant. Learn more about the safety and efficacy of Rejoyn here.2
Safety Information for Rejoyn
Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.
Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.
Rejoyn is indicated to be an adjunct to antidepressant medication. Adding Rejoyn to your patient’s care plan helps target dysregulated connectivity between the amygdala and the prefrontal cortex—all from a smartphone. Rejoyn is not intended to be used as a standalone therapy or a substitute for medications. Patients should continue their current treatment as directed.1
Privacy guardrails are in place to ensure patient data remain safe and protected while using Rejoyn. Please see our Privacy Policy for more information.
You can learn more by attending a peer-led virtual program. During the program, you will:
- Gain insight into the need for innovative treatments that may address neural dysfunction in MDD
- Discover the unique mechanism of action of Rejoyn1
- Explore the clinical evidence supporting the efficacy and safety of Rejoyn2
- Learn how to prescribe Rejoyn and augment your patient's MDD treatment without additional side effects2
Register for the program here.
Contact
To reach an Otsuka MSL, complete this form. Once the form is submitted, an MSL will reach out to you to schedule a live or virtual visit.
To reach a Rejoyn Patient Support nurse, call 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays. If you call outside of operating hours, you can leave a message and someone will get back to you the following business day.
You can reach tech support by calling 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays.
To report an adverse event or product quality complaint, please call 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays.
Find answers to other common questions
Read through the patient FAQs to find answers and ways to help support your patients through treatment.
End-to-end nurse support
Patients can call the nurse support line at 1-833-Y-REJOYN (1-833-973-5696) for assistance throughout their 6-week treatment with Rejoyn. Available Monday through Friday, 8 AM to 8 PM ET, excluding holidays.
